Townsquare Capital LLC Purchases 44,044 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Townsquare Capital LLC boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 74.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 103,223 shares of the biopharmaceutical company’s stock after purchasing an additional 44,044 shares during the period. Townsquare Capital LLC owned about 0.08% of Halozyme Therapeutics worth $5,908,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its holdings in Halozyme Therapeutics by 24.0% during the first quarter. Janus Henderson Group PLC now owns 531,125 shares of the biopharmaceutical company’s stock worth $21,604,000 after acquiring an additional 102,911 shares during the period. Swedbank AB purchased a new position in shares of Halozyme Therapeutics in the 1st quarter worth about $13,927,000. Boston Partners grew its position in Halozyme Therapeutics by 14.1% during the first quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company’s stock valued at $25,500,000 after buying an additional 77,976 shares during the period. DekaBank Deutsche Girozentrale increased its holdings in Halozyme Therapeutics by 9.8% during the first quarter. DekaBank Deutsche Girozentrale now owns 54,907 shares of the biopharmaceutical company’s stock worth $2,220,000 after buying an additional 4,907 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO stock opened at $48.47 on Friday. The firm has a 50 day moving average of $53.72 and a 200-day moving average of $53.67. The firm has a market capitalization of $6.17 billion, a P/E ratio of 16.05, a price-to-earnings-growth ratio of 0.43 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Piper Sandler raised their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Benchmark reiterated a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Finally, JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $9,254,244.56. This represents a 5.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 60,000 shares of company stock worth $3,425,000 in the last three months. 2.70% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.